作者
Pier Vitale Nuzzo, Jacob E Berchuck, Keegan Korthauer, Sandor Spisak, Amin H Nassar, Sarah Abou Alaiwi, Ankur Chakravarthy, Shu Yi Shen, Ziad Bakouny, Francesco Boccardo, John Steinharter, Gabrielle Bouchard, Catherine R Curran, Wenting Pan, Sylvan C Baca, Ji-Heui Seo, Gwo-Shu Mary Lee, M Dror Michaelson, Steven L Chang, Sushrut S Waikar, Guru Sonpavde, Rafael A Irizarry, Mark Pomerantz, Daniel D De Carvalho, Toni K Choueiri, Matthew L Freedman
发表日期
2020/7/1
期刊
Nature medicine
卷号
26
期号
7
页码范围
1041-1043
出版商
Nature Publishing Group US
简介
Improving early cancer detection has the potential to substantially reduce cancer-related mortality. Cell-free methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP–seq) is a highly sensitive assay capable of detecting early-stage tumors. We report accurate classification of patients across all stages of renal cell carcinoma (RCC) in plasma (area under the receiver operating characteristic (AUROC) curve of 0.99) and demonstrate the validity of this assay to identify patients with RCC using urine cell-free DNA (cfDNA; AUROC of 0.86).
学术搜索中的文章
PV Nuzzo, JE Berchuck, K Korthauer, S Spisak… - Nature medicine, 2020
Author Correction: Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes*
PV Nuzzo, JE Berchuck, K Korthauer, S Spisak… - Nature Medicine, 2020